Follow
Tina Gruosso
Title
Cited by
Cited by
Year
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response
B Mateescu, L Batista, M Cardon, T Gruosso, Y De Feraudy, O Mariani, ...
Nature medicine 17 (12), 1627-1635, 2011
5042011
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
T Gruosso, M Gigoux, VSK Manem, N Bertos, D Zuo, I Perlitch, SMI Saleh, ...
The Journal of clinical investigation 129 (4), 1785-1800, 2019
3222019
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
F Klauschen, KR Müller, A Binder, M Bockmayr, M Hägele, P Seegerer, ...
Seminars in cancer biology 52, 151-157, 2018
1532018
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression
O Maller, AP Drain, AS Barrett, S Borgquist, B Ruffell, I Zakharevich, ...
Nature Materials, 1-12, 2020
1502020
Chronic oxidative stress promotes H2 AX protein degradation and enhances chemosensitivity in breast cancer patients
T Gruosso, V Mieulet, M Cardon, B Bourachot, Y Kieffer, F Devun, ...
EMBO molecular medicine 8 (5), 527-549, 2016
1392016
Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach
Y Bareche, L Buisseret, T Gruosso, E Girard, D Venet, F Dupont, ...
JNCI: Journal of the National Cancer Institute 112 (7), 708-719, 2020
1362020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Z Kos, E Roblin, RS Kim, S Michiels, BD Gallas, W Chen, KK van de Vijver, ...
NPJ breast cancer 6 (1), 1-16, 2020
1312020
Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer
X Li, T Gruosso, D Zuo, A Omeroglu, S Meterissian, MC Guiot, A Salazar, ...
Proceedings of the National Academy of Sciences 116 (9), 3678-3687, 2019
1182019
HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells
PE Rosenstiel, T Gruosso, AM Letourneau, JJ Chan, A LeBlanc, M Husain, ...
Kidney international 74 (8), 1049-1058, 2008
582008
MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas
T Gruosso, C Garnier, S Abelanet, Y Kieffer, V Lemesre, D Bellanger, ...
Nature communications 6 (1), 1-15, 2015
522015
Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss
B Murali, Q Ren, X Luo, DV Faget, C Wang, RM Johnson, T Gruosso, ...
Cancer research 78 (19), 5618-5630, 2018
502018
KIBRA (WWC1) Is a metastasis suppressor gene affected by chromosome 5q loss in triple-negative breast cancer
JF Knight, VYC Sung, E Kuzmin, AL Couzens, DA de Verteuil, ...
Cell reports 22 (12), 3191-3205, 2018
472018
Ovarian cancer emerging subtypes: role of oxidative stress and fibrosis in tumour development and response to treatment
L Batista, T Gruosso, F Mechta-Grigoriou
The international journal of biochemistry & cell biology 45 (6), 1092-1098, 2013
352013
Identification of interacting stromal axes in triple-negative breast cancer
SMI Saleh, N Bertos, T Gruosso, M Gigoux, M Souleimanova, H Zhao, ...
Cancer research 77 (17), 4673-4683, 2017
292017
AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced …
TA Yap, NJ Lakhani, DV Araujo, J Rodon Ahnert, SR Chandana, ...
Journal of Clinical Oncology 38 (15_suppl), 3587-3587, 2020
202020
The human adenovirus type 5 E4orf4 protein targets two phosphatase regulators of the Hippo signaling pathway
MZ Mui, Y Zhou, P Blanchette, N Chughtai, JF Knight, T Gruosso, ...
Journal of virology 89 (17), 8855-8870, 2015
152015
THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE …
R Lafyatis, R Spiera, R Domsic, A Papazoglou, C Ligon, CMZ Morse, ...
Annals of the Rheumatic Diseases 79 (Suppl 1), 390-391, 2020
142020
Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
AH Mohammad, SH Kim, N Bertos, W El-Assaad, I Nandi, H Smith, J Yang, ...
Molecular Cancer Research 18 (10), 1477-1490, 2020
112020
P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement …
T Yap, D Araujo, D Wood, JF Denis, T Gruosso, G Tremblay, ...
Journal for ImmunoTherapy of Cancer 8 (Suppl 1), 2020
82020
Predicting relapse in patients with Triple Negative Breast Cancer (TNBC) using a deep-learning approach
G Yu, X Li, TF He, T Gruosso, D Zuo, M Souleimanova, VM Ramos, ...
Frontiers in Physiology 11, 2020
82020
The system can't perform the operation now. Try again later.
Articles 1–20